Therapeutic Plasma Exchange Versus FcRn Inhibition in Autoimmune Disease

Area of Science:

• Immunology
• Autoimmune Diseases
• Pharmacology

Background:

• Therapeutic plasma exchange (TPE or PLEX) removes autoantibodies in autoimmune diseases.
• Neonatal Fc receptor (FcRn) inhibitors selectively target and reduce immunoglobulin G (IgG) autoantibodies by inhibiting IgG recycling.

Purpose of the Study:

• To compare the efficacy, safety, and clinical utility of PLEX and FcRn inhibitors in autoimmune diseases.
• To discuss the distinct advantages and disadvantages of each therapeutic approach in various clinical scenarios.

Main Methods:

• Review of scientific literature on PLEX and FcRn inhibitors in autoimmune diseases.
• Expert discussion comparing non-selective plasma protein depletion (PLEX) with selective IgG removal (FcRn inhibition).

Main Results:

• FcRn inhibitors provide specific IgG reduction, similar to PLEX, with less invasive requirements and fewer impacts on other plasma proteins.
• PLEX remains preferred for removing non-IgG antibodies or when plasma protein repletion is necessary.
• FcRn inhibitors have not been studied in acute flares or crisis states of IgG-mediated diseases.

Conclusions:

• FcRn inhibitors represent a targeted approach to IgG reduction in autoimmune diseases, offering potential advantages over PLEX in specific contexts.
• The choice between PLEX and FcRn inhibition depends on the specific disease, therapeutic goals, and patient needs.